A Phase 2 interventional study of Phentolamine Mesylate Ophthalmic Solution 1.0% and Phentolamine Mesylate Ophthalmic Solution 0.5% in Night Vision Complaints, Decrease in Night Vision and Disturbance; Vision, Loss, sponsored by Opus Genetics, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Opus Genetics, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objectives of this study are:
Randomized, double-masked, multiple dose Phase 2 parallel evaluation of the safety and efficacy of phentolamine mesylate (PM) ophthalmic solution in 60 subjects with severe night vision complaints, evaluating ocular and systemic safety and efficacy following administration of phentolamine mesylate (.05% or 1%) in both eyes for 15 days.
Subjects were randomized into three groups with a 1:1:1 randomization. The groups received either (1) phentolamine mesylate ophthalmic solution 0.5%, (2) phentolamine mesylate ophthalmic solution 1.0%, or (3) placebo, once daily (QD) for 15 days. The treatment period was 15 days, plus 6 additional days over the next 14 days. After 15 days, all subjects were given the opportunity to receive an additional 6 doses of 1.0% phentolamine mesylate to be taken once daily as needed over the next two weeks. There was a post-dosing follow-up evaluation 7 days after the last dose. Study participants completed a night vision questionnaire at pre-treatment and after 15 and 29 days.
Efficacy evaluations included contrast sensitivity (mesopic, with and without glare), mesopic distance high contrast visual acuity (HCVA) and mesopic distance low contrast visual acuity (LCVA). Safety evaluations included photopic distance HCVA, a complete ophthalmic examination and measurement of heart rate and blood pressure.
Opus Genetics, Inc is the lead sponsor of 17 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered once daily in both eyes for 15 days
Other: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Administered once daily in both eyes for 15 days
Drug: Phentolamine Mesylate Ophthalmic Solution 0.5%
Administered once daily in both eyes for 15 days
Drug: Phentolamine Mesylate Ophthalmic Solution 1.0%
Phentolamine mesylate (Nyxol) ophthalmic solution 1.0% is a non-selective alpha-1 and alpha-2 adrenergic antagonist
Also known as: Nyxol®, Nyxol
Phentolamine mesylate (Nyxol) ophthalmic solution 0.5% is a non-selective alpha-1 and alpha-2 adrenergic antagonist
Also known as: Nyxol®, Nyxol
Placebo (vehicle) is a sterile, isotonic, buffered aqueous solution containing mannitol and sodium acetate
Proportion of Eyes With ≥ 0.3 Log Increase in Mesopic Contrast Sensitivities for at Least 2 HACSS Frequencies
Proportion of eyes with an increase ≥ 0.3 log (2 or more patches) in mesopic contrast sensitivity with glare at two or more frequencies at 1.5, 3, 6, 12, and 18 cycles per degree, measured with the HACSS methodology (categorical analysis)
Time frame: Postdose Day 1, 4, 8, 15, and Day 15 (LOCF=Last Observation Carried Forward)
Pupil Diameter - Change From Day 1 Pre-Dose Baseline
Time frame: Day 1 post-dose and Days 4, 8, and 15
Mean Mesopic Contrast Sensitivity With Glare at Frequencies of 1.5, 3, 6, 12, and 18 Cycles Per Degree, Measured With the HACSS Methodology in LogCS Scale - Change From Day 1 Pre-Dose Baseline
At screening, contralateral illumination contrast sensitivity (HACSS) was measured to determine subject/eye eligibility. The Day 1 predose HACSS LogCS value served as the baseline for assessing improvement. At each post-dose visit (Days 1, 4, 8, 15), eyes with an improvement of at least 0.3 LogCS in mesopic contrast sensitivity with glare compared to baseline were summarized across all 5 frequencies (1.5, 3, 6, 12, and 18 cycles per degree). The Log CS (Logarithmic Contrast Sensitivity) scale measures how faintly an object can be distinguished from its background, calculated as the logarithm of contrast sensitivity (CS = 1 ÷ contrast threshold). Higher values indicate the ability to see highly faded, low-contrast images.
Time frame: 15 Days
Mesopic Contrast Sensitivity Without Glare at 1 or More Frequencies at 1.5, 3, 6, 12, and 18 Cycles Per Degree, Measured With the HACSS Methodology in LogCS Scale - Mean Change From Day 1 Pre-Dose Baseline
At screening, contralateral illumination contrast sensitivity (HACSS) was measured to determine subject/eye eligibility. The Day 1 predose HACSS LogCS value served as the baseline for assessing improvement. Only eyes with at least 0.3 LogCS improvement at 2 or more frequencies were counted as showing overall improvement. At each postdose visit (Days 1, 4, 8, 15), eyes with an improvement of at least 0.3 LogCS in mesopic contrast sensitivity with glare compared to baseline were across all 5 frequencies 1.5, 3, 6, 12, and 18 cycles per degree.
Time frame: Day 1 post-dose and Days 4, 8, and 15
Mesopic Distance High Contrast Visual Acuity (HCVA), Measured With Electronic Early Treatment Diabetic Retinopathy Study (eETDRS) Charts - Change From Day 1 Pre-Dose Baseline
Time frame: Day 1 post-dose and Days 4, 8, and 15
Mesopic Distance Low Contrast Visual Acuity (LCVA), Measured With eETDRS Charts - Change From Day 1 Pre-Dose Baseline
Time frame: Day 1 post-dose and Days 4, 8, and 15
Subjective Evaluations of Vision (NEI Vision Function) at Follow-up (Day 32)
NEI visual functioning questionnaire-25 (VFQ-25) Adapted for Dim Light Vision was conducted at the follow-up visit on Day 32. The frequency of categorical answers was summarized by treatment for each question. The questions are on a scale that ranges from 1-2, 1-2, 1-5, or 1-6 with 1 being the best outcome and 6 being the worst. Q14, Q15: 1-2; Q1, Q3, Q16, Q17, Q18, Q19, Q20, Q21, Q22, Q23: 1-5; Q2, Q4, Q5, Q6, Q7, Q8, Q9, Q10, Q11, Q12, Q13, Q14a, Q14b, Q14c, Q15, Q15a: 1-6. Questions 2 through 15a on the VFQ related to the subject's assessment of how much difficulty, if any, the subject has doing certain activities in dim light or at night, particularly driving (Questions 14c, 15, and 15a); the remaining questions related to how things the subject does may be affected by their vision in dim light or at night.
Time frame: Day 32
| Milestone | Placebo | Phentolamine Mesylate Ophthalmic Solution 0.5% | Phentolamine Mesylate Ophthalmic Solution 1.0% |
|---|---|---|---|
| Started | 20 | 20 | 20 |
| Completed | 18 | 20 | 20 |
| Not completed | 2 | 0 | 0 |
| Milestone | Placebo | Phentolamine Mesylate Ophthalmic Solution 0.5% | Phentolamine Mesylate Ophthalmic Solution 1.0% |
|---|---|---|---|
| Started | 18 | 20 | 20 |
| Completed | 18 | 19 | 20 |
| Not completed | 0 | 1 | 0 |
Proportion of eyes with an increase ≥ 0.3 log (2 or more patches) in mesopic contrast sensitivity with glare at two or more frequencies at 1.5, 3, 6, 12, and 18 cycles per degree, measured with the HACSS methodology (categorical analysis)
| Eyes | Placebo | Phentolamine Mesylate Ophthalmic Solution 0.5% | Phentolamine Mesylate Ophthalmic Solution 1.0% |
|---|---|---|---|
| Day 1 Postdose | 5 | 8 | 3 |
| Day 4 Postdose | 6 | 7 | 4 |
| Day 8 Postdose | 7 | 10 | 9 |
| Day 15 Postdose | 6 | 15 | 11 |
| Day 15 Postdose (LOCF) | 7 | 15 | 11 |
| mm | Placebo | Phentolamine Mesylate Ophthalmic Solution 0.5% | Phentolamine Mesylate Ophthalmic Solution 1.0% |
|---|---|---|---|
| Day 1 Postdose | 0.16 ± 0.828 | -0.82 ± 0.829 | -1.07 ± 0.651 |
| Day 4 Postdose | 0.02 ± 0.833 | -1.17 ± 0.751 | -1.22 ± 0.863 |
| Day 8 Postdose | -0.07 ± 0.969 | -0.92 ± 0.956 | -0.93 ± 0.736 |
| Day 15 Postdose | 0.17 ± 1.232 | -0.51 ± 0.639 | -0.81 ± 0.846 |
At screening, contralateral illumination contrast sensitivity (HACSS) was measured to determine subject/eye eligibility. The Day 1 predose HACSS LogCS value served as the baseline for assessing improvement. At each post-dose visit (Days 1, 4, 8, 15), eyes with an improvement of at least 0.3 LogCS in mesopic contrast sensitivity with glare compared to baseline were summarized across all 5 frequencies (1.5, 3, 6, 12, and 18 cycles per degree). The Log CS (Logarithmic Contrast Sensitivity) scale measures how faintly an object can be distinguished from its background, calculated as the logarithm of contrast sensitivity (CS = 1 ÷ contrast threshold). Higher values indicate the ability to see highly faded, low-contrast images.
| Log CS | Placebo | Phentolamine Mesylate Ophthalmic Solution 0.5% | Phentolamine Mesylate Ophthalmic Solution 1.0% |
|---|---|---|---|
| Day 1 post-dose, 1.5 | 0.00 ± 0.234 | 0.01 ± 0.257 | -0.09 ± 0.310 |
| Day 4 post-dose, 1.5 | -0.03 ± 0.388 | -0.02 ± 0.293 | -0.06 ± 0.288 |
| Day 8 post-dose, 1.5 | -0.11 ± 0.343 | 0.02 ± 0.385 | 0.04 ± 0.297 |
| Day 15 post-dose, 1.5 | -0.08 ± 0.351 | -0.01 ± 0.391 | 0.06 ± 0.310 |
| Day 1 post-dose, 3.0 | -0.08 ± 0.222 | 0.01 ± 0.202 | -0.09 ± 0.230 |
| Day 4 post-dose, 3.0 | -0.08 ± 0.323 | 0.01 ± 0.282 | -0.01 ± 0.211 |
| Day 8 post-dose, 3.0 | -0.08 ± 0.324 | 0.04 ± 0.325 | 0.03 ± 0.256 |
| Day 15 post-dose, 3.0 | -0.10 ± 0.362 | 0.03 ± 0.316 | -0.01 ± 0.285 |
| Day 1 post-dose, 6.0 | 0.03 ± 0.278 | 0.05 ± 0.163 | -0.11 ± 0.292 |
| Day 4 post-dose, 6.0 | -0.02 ± 0.320 | 0.03 ± 0.237 | -0.05 ± 0.296 |
| Day 8 post-dose, 6.0 | -0.06 ± 0.341 | 0.04 ± 0.276 | 0.00 ± 0.310 |
| Day 15 post-dose, 6.0 | -0.05 ± 0.399 | 0.03 ± 0.378 | -0.02 ± 0.336 |
| Day 1 post-dose, 12.0 | -0.01 ± 0.287 | 0.03 ± 0.212 | -0.13 ± 0.335 |
| Day 4 post-dose, 12.0 | -0.04 ± 0.273 | 0.02 ± 0.298 | -0.10 ± 0.397 |
| Day 8 post-dose, 12.0 | -0.02 ± 0.294 | 0.05 ± 0.317 | -0.03 ± 0.341 |
| Day 15 post-dose, 12.0 | -0.04 ± 0.320 | 0.01 ± 0.337 | -0.01 ± 0.348 |
| Day 1 post-dose, 18.0 | -0.04 ± 0.214 | 0.00 ± 0.333 | -0.05 ± 0.275 |
| Day 4 post-dose, 18.0 | -0.05 ± 0.236 | -0.05 ± 0.271 | -0.02 ± 0.376 |
| Day 8 post-dose, 18.0 | -0.01 ± 0.255 | -0.01 ± 0.377 | 0.02 ± 0.343 |
| Day 15 post-dose, 18.0 | 0.00 ± 0.289 | 0.11 ± 0.368 | 0.03 ± 0.325 |
At screening, contralateral illumination contrast sensitivity (HACSS) was measured to determine subject/eye eligibility. The Day 1 predose HACSS LogCS value served as the baseline for assessing improvement. Only eyes with at least 0.3 LogCS improvement at 2 or more frequencies were counted as showing overall improvement. At each postdose visit (Days 1, 4, 8, 15), eyes with an improvement of at least 0.3 LogCS in mesopic contrast sensitivity with glare compared to baseline were across all 5 frequencies 1.5, 3, 6, 12, and 18 cycles per degree.
| Log CS | Placebo | Phentolamine Mesylate Ophthalmic Solution 0.5% | Phentolamine Mesylate Ophthalmic Solution 1.0% |
|---|---|---|---|
| Day 1 Postdose, 1.5 | 0.00 ± 0.189 | -0.02 ± 0.200 | -0.14 ± 0.222 |
| Day 4 Postdose, 1.5 | -0.06 ± 0.316 | -0.03 ± 0.272 | -0.04 ± 0.231 |
| Day 8 Postdose, 1.5 | -0.06 ± 0.276 | -0.01 ± 0.347 | -0.02 ± 0.307 |
| Day 15 Postdose, 1.5 | -0.03 ± 0.404 | 0.02 ± 0.313 | -0.02 ± 0.275 |
| Day 1 Postdose, 3.0 | -0.03 ± 0.229 | 0.00 ± 0.156 | -0.06 ± 0.234 |
| Day 4 Postdose, 3.0 | -0.08 ± 0.369 | 0.01 ± 0.208 | 0.02 ± 0.203 |
| Day 8 Postdose, 3.0 | -0.06 ± 0.345 | -0.03 ± 0.319 | 0.00 ± 0.236 |
| Day 15 Postdose, 3.0 | -0.07 ± 0.353 | -0.01 ± 0.275 | 0.01 ± 0.250 |
| Day 1 Postdose, 6.0 | -0.01 ± 0.216 | 0.01 ± 0.171 | -0.02 ± 0.170 |
| Day 4 Postdose, 6.0 | -0.06 ± 0.376 | 0.01 ± 0.246 | 0.00 ± 0.202 |
| Day 8 Postdose, 6.0 | -0.03 ± 0.317 | 0.03 ± 0.238 | 0.05 ± 0.202 |
| Day 15 Postdose, 6.0 | -0.06 ± 0.356 | 0.05 ± 0.227 | 0.02 ± 0.218 |
| Day 1 Postdose, 12.0 | -0.05 ± 0.225 | -0.01 ± 0.247 | -0.04 ± 0.196 |
| Day 4 Postdose, 12.0 | -0.10 ± 0.280 | -0.02 ± 0.297 | 0.03 ± 0.271 |
| Day 8 Postdose, 12.0 | -0.01 ± 0.312 | 0.01 ± 0.370 | 0.05 ± 0.229 |
| Day 15 Postdose, 12.0 | -0.08 ± 0.325 | 0.08 ± 0.381 | 0.03 ± 0.227 |
| Day 1 Postdose, 18.0 | -0.02 ± 0.234 | -0.03 ± 0.246 | 0.04 ± 0.245 |
| Day 4 Postdose, 18.0 | -0.04 ± 0.238 | -0.08 ± 0.319 | 0.04 ± 0.313 |
| Day 8 Postdose, 18.0 | 0.03 ± 0.270 | -0.03 ± 0.378 | 0.02 ± 0.292 |
| Day 15 Postdose, 18.0 | -0.01 ± 0.285 | 0.13 ± 0.372 | 0.04 ± 0.285 |
| ETDRS Letter Score | Placebo | Phentolamine Mesylate Ophthalmic Solution 0.5% | Phentolamine Mesylate Ophthalmic Solution 1.0% |
|---|---|---|---|
| Day 1 Postdose | 1.175 ± 3.7272 | 2.025 ± 9.3548 | 0.700 ± 4.0077 |
| Day 4 Postdose | 2.025 ± 4.6492 | 3.350 ± 9.8438 | 2.600 ± 3.6006 |
| Day 8 Postdose | 2.050 ± 4.5683 | 3.895 ± 9.9886 | 2.825 ± 3.9281 |
| Day 15 Postdose | 2.421 ± 4.8582 | 4.947 ± 9.3951 | 3.825 ± 6.0123 |
| ETDRS Letter Score | Placebo | Phentolamine Mesylate Ophthalmic Solution 0.5% | Phentolamine Mesylate Ophthalmic Solution 1.0% |
|---|---|---|---|
| Day 1 Postdose | 1.750 ± 4.8185 | 0.975 ± 5.4419 | 1.325 ± 4.8272 |
| Day 4 Postdose | 3.100 ± 6.1135 | 1.350 ± 6.0279 | 5.825 ± 7.1607 |
| Day 8 Postdose | 3.650 ± 6.0703 | 1.421 ± 7.3875 | 7.050 ± 7.3063 |
| Day 15 Postdose | 4.838 ± 6.4400 | 5.184 ± 7.8288 | 7.100 ± 9.1085 |
NEI visual functioning questionnaire-25 (VFQ-25) Adapted for Dim Light Vision was conducted at the follow-up visit on Day 32. The frequency of categorical answers was summarized by treatment for each question. The questions are on a scale that ranges from 1-2, 1-2, 1-5, or 1-6 with 1 being the best outcome and 6 being the worst. Q14, Q15: 1-2; Q1, Q3, Q16, Q17, Q18, Q19, Q20, Q21, Q22, Q23: 1-5; Q2, Q4, Q5, Q6, Q7, Q8, Q9, Q10, Q11, Q12, Q13, Q14a, Q14b, Q14c, Q15, Q15a: 1-6. Questions 2 through 15a on the VFQ related to the subject's assessment of how much difficulty, if any, the subject has doing certain activities in dim light or at night, particularly driving (Questions 14c, 15, and 15a); the remaining questions related to how things the subject does may be affected by their vision in dim light or at night.
| Participants | Phentolamine Mesylate Ophthalmic Solution 1.0% |
|---|---|
| Q1: In general, would you say your overall health is: — 1 | 20 |
| Q1: In general, would you say your overall health is: — 2 | 23 |
| Q1: In general, would you say your overall health is: — 3 | 14 |
| Q1: In general, would you say your overall health is: — 4 | 1 |
| Q1: In general, would you say your overall health is: — 5 | 0 |
| Q1: In general, would you say your overall health is: — 6 | 0 |
| Q2: At the present time, would you say your eyesight using both eyes is: — 1 | 5 |
| Q2: At the present time, would you say your eyesight using both eyes is: — 2 | 19 |
| Q2: At the present time, would you say your eyesight using both eyes is: — 3 | 28 |
| Q2: At the present time, would you say your eyesight using both eyes is: — 4 | 6 |
| Q2: At the present time, would you say your eyesight using both eyes is: — 5 | 0 |
| Q2: At the present time, would you say your eyesight using both eyes is: — 6 | 0 |
| Q3: How much of the time do you worry about your eyesight? — 1 | 4 |
| Q3: How much of the time do you worry about your eyesight? — 2 | 23 |
| Q3: How much of the time do you worry about your eyesight? — 3 | 25 |
| Q3: How much of the time do you worry about your eyesight? — 4 | 6 |
| Q3: How much of the time do you worry about your eyesight? — 5 | 0 |
| Q3: How much of the time do you worry about your eyesight? — 6 | 0 |
| Q4: How much difficulty do you have reading ordinary print in newspapers? Would you say you have: — 1 | 4 |
| Q4: How much difficulty do you have reading ordinary print in newspapers? Would you say you have: — 2 | 25 |
| Q4: How much difficulty do you have reading ordinary print in newspapers? Would you say you have: — 3 | 20 |
| Q4: How much difficulty do you have reading ordinary print in newspapers? Would you say you have: — 4 | 9 |
| Q4: How much difficulty do you have reading ordinary print in newspapers? Would you say you have: — 5 | 0 |
| Q4: How much difficulty do you have reading ordinary print in newspapers? Would you say you have: — 6 | 0 |
| Q5: How much difficulty do you have doing work or hobbies that require you to see well up close... — 1 | 13 |
| Q5: How much difficulty do you have doing work or hobbies that require you to see well up close... — 2 | 20 |
| Q5: How much difficulty do you have doing work or hobbies that require you to see well up close... — 3 | 21 |
| Q5: How much difficulty do you have doing work or hobbies that require you to see well up close... — 4 | 4 |
| Q5: How much difficulty do you have doing work or hobbies that require you to see well up close... — 5 | 0 |
| Q5: How much difficulty do you have doing work or hobbies that require you to see well up close... — 6 | 0 |
| Q6: Because of your eyesight, how much difficulty do you have finding something on a crowded shelf? — 1 | 12 |
| Q6: Because of your eyesight, how much difficulty do you have finding something on a crowded shelf? — 2 | 27 |
| Q6: Because of your eyesight, how much difficulty do you have finding something on a crowded shelf? — 3 | 16 |
| Q6: Because of your eyesight, how much difficulty do you have finding something on a crowded shelf? — 4 | 3 |
| Q6: Because of your eyesight, how much difficulty do you have finding something on a crowded shelf? — 5 | 0 |
| Q6: Because of your eyesight, how much difficulty do you have finding something on a crowded shelf? — 6 | 0 |
| Q7: How much difficulty do you have reading street signs or the names of stores? — 1 | 6 |
| Q7: How much difficulty do you have reading street signs or the names of stores? — 2 | 22 |
| Q7: How much difficulty do you have reading street signs or the names of stores? — 3 | 23 |
| Q7: How much difficulty do you have reading street signs or the names of stores? — 4 | 7 |
| Q7: How much difficulty do you have reading street signs or the names of stores? — 5 | 0 |
| Q7: How much difficulty do you have reading street signs or the names of stores? — 6 | 0 |
| Q8: Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs... — 1 | 20 |
| Q8: Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs... — 2 | 22 |
| Q8: Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs... — 3 | 15 |
| Q8: Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs... — 4 | 1 |
| Q8: Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs... — 5 | 0 |
| Q8: Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs... — 6 | 0 |
| Q9: Because of your eyesight, how much difficulty do you have noticing objects off to the side... — 1 | 14 |
| Q9: Because of your eyesight, how much difficulty do you have noticing objects off to the side... — 2 | 23 |
| Q9: Because of your eyesight, how much difficulty do you have noticing objects off to the side... — 3 | 18 |
| Q9: Because of your eyesight, how much difficulty do you have noticing objects off to the side... — 4 | 3 |
| Q9: Because of your eyesight, how much difficulty do you have noticing objects off to the side... — 5 | 0 |
| Q9: Because of your eyesight, how much difficulty do you have noticing objects off to the side... — 6 | 0 |
| Q10: Because of your eyesight, how much difficulty do you have seeing how people react to things... — 1 | 24 |
| Q10: Because of your eyesight, how much difficulty do you have seeing how people react to things... — 2 | 20 |
| Q10: Because of your eyesight, how much difficulty do you have seeing how people react to things... — 3 | 12 |
| Q10: Because of your eyesight, how much difficulty do you have seeing how people react to things... — 4 | 2 |
| Q10: Because of your eyesight, how much difficulty do you have seeing how people react to things... — 5 | 0 |
| Q10: Because of your eyesight, how much difficulty do you have seeing how people react to things... — 6 | 0 |
| Q11: Because of your eyesight, how much difficulty do you have picking out and matching your own... — 1 | 30 |
| Q11: Because of your eyesight, how much difficulty do you have picking out and matching your own... — 2 | 19 |
| Q11: Because of your eyesight, how much difficulty do you have picking out and matching your own... — 3 | 7 |
| Q11: Because of your eyesight, how much difficulty do you have picking out and matching your own... — 4 | 2 |
| Q11: Because of your eyesight, how much difficulty do you have picking out and matching your own... — 5 | 0 |
| Q11: Because of your eyesight, how much difficulty do you have picking out and matching your own... — 6 | 0 |
| Q12: Because of your eyesight, how much difficulty do you have visiting with people in their homes.. — 1 | 32 |
| Q12: Because of your eyesight, how much difficulty do you have visiting with people in their homes.. — 2 | 17 |
| Q12: Because of your eyesight, how much difficulty do you have visiting with people in their homes.. — 3 | 7 |
| Q12: Because of your eyesight, how much difficulty do you have visiting with people in their homes.. — 4 | 2 |
| Q12: Because of your eyesight, how much difficulty do you have visiting with people in their homes.. — 5 | 0 |
| Q12: Because of your eyesight, how much difficulty do you have visiting with people in their homes.. — 6 | 0 |
| Q13: Because of your eyesight, how much difficulty do you have going out to see movies, plays, or... — 1 | 26 |
| Q13: Because of your eyesight, how much difficulty do you have going out to see movies, plays, or... — 2 | 17 |
| Q13: Because of your eyesight, how much difficulty do you have going out to see movies, plays, or... — 3 | 13 |
| Q13: Because of your eyesight, how much difficulty do you have going out to see movies, plays, or... — 4 | 2 |
| Q13: Because of your eyesight, how much difficulty do you have going out to see movies, plays, or... — 5 | 0 |
| Q13: Because of your eyesight, how much difficulty do you have going out to see movies, plays, or... — 6 | 0 |
| Q14: I'd like to ask about driving a car. Are you currently driving , at least once in a while? — 1 | 53 |
| Q14: I'd like to ask about driving a car. Are you currently driving , at least once in a while? — 2 | 5 |
| Q14: I'd like to ask about driving a car. Are you currently driving , at least once in a while? — 3 | 0 |
| Q14: I'd like to ask about driving a car. Are you currently driving , at least once in a while? — 4 | 0 |
| Q14: I'd like to ask about driving a car. Are you currently driving , at least once in a while? — 5 | 0 |
| Q14: I'd like to ask about driving a car. Are you currently driving , at least once in a while? — 6 | 0 |
| Q14a: IF NO: Have you never driven a car or have you given up driving? — 1 | 1 |
| Q14a: IF NO: Have you never driven a car or have you given up driving? — 2 | 4 |
| Q14a: IF NO: Have you never driven a car or have you given up driving? — 3 | 0 |
| Q14a: IF NO: Have you never driven a car or have you given up driving? — 4 | 0 |
| Q14a: IF NO: Have you never driven a car or have you given up driving? — 5 | 0 |
| Q14a: IF NO: Have you never driven a car or have you given up driving? — 6 | 0 |
| Q14b: IF GAVE UP DRIVING: Was that mainly because of your eyesight, mainly for some other reason... — 1 | 2 |
| Q14b: IF GAVE UP DRIVING: Was that mainly because of your eyesight, mainly for some other reason... — 2 | 1 |
| Q14b: IF GAVE UP DRIVING: Was that mainly because of your eyesight, mainly for some other reason... — 3 | 1 |
| Q14b: IF GAVE UP DRIVING: Was that mainly because of your eyesight, mainly for some other reason... — 4 | 0 |
| Q14b: IF GAVE UP DRIVING: Was that mainly because of your eyesight, mainly for some other reason... — 5 | 0 |
| Q14b: IF GAVE UP DRIVING: Was that mainly because of your eyesight, mainly for some other reason... — 6 | 0 |
| Q14c: IF CURRENTLY DRIVING: How much difficulty do you have driving during the daytime in... — 1 | 16 |
| Q14c: IF CURRENTLY DRIVING: How much difficulty do you have driving during the daytime in... — 2 | 27 |
| Q14c: IF CURRENTLY DRIVING: How much difficulty do you have driving during the daytime in... — 3 | 10 |
| Q14c: IF CURRENTLY DRIVING: How much difficulty do you have driving during the daytime in... — 4 | 0 |
| Q14c: IF CURRENTLY DRIVING: How much difficulty do you have driving during the daytime in... — 5 | 0 |
| Q14c: IF CURRENTLY DRIVING: How much difficulty do you have driving during the daytime in... — 6 | 0 |
| Q15: How much difficulty do you have driving at night? Would you say you have: — 1 | 5 |
| Q15: How much difficulty do you have driving at night? Would you say you have: — 2 | 18 |
| Q15: How much difficulty do you have driving at night? Would you say you have: — 3 | 22 |
| Q15: How much difficulty do you have driving at night? Would you say you have: — 4 | 8 |
| Q15: How much difficulty do you have driving at night? Would you say you have: — 5 | 0 |
| Q15: How much difficulty do you have driving at night? Would you say you have: — 6 | 0 |
| Q15a: How much difficulty do you have driving in difficult conditions, such as in bad weather... — 1 | 2 |
| Q15a: How much difficulty do you have driving in difficult conditions, such as in bad weather... — 2 | 23 |
| Q15a: How much difficulty do you have driving in difficult conditions, such as in bad weather... — 3 | 14 |
| Q15a: How much difficulty do you have driving in difficult conditions, such as in bad weather... — 4 | 13 |
| Q15a: How much difficulty do you have driving in difficult conditions, such as in bad weather... — 5 | 0 |
| Q15a: How much difficulty do you have driving in difficult conditions, such as in bad weather... — 6 | 0 |
| Q16: Do you accomplish less than you would like because of your vision? — 1 | 0 |
| Q16: Do you accomplish less than you would like because of your vision? — 2 | 7 |
| Q16: Do you accomplish less than you would like because of your vision? — 3 | 16 |
| Q16: Do you accomplish less than you would like because of your vision? — 4 | 24 |
| Q16: Do you accomplish less than you would like because of your vision? — 5 | 11 |
| Q16: Do you accomplish less than you would like because of your vision? — 6 | 0 |
| Q17: Are you limited in how long you can work or do other activities because of your vision? — 1 | 0 |
| Q17: Are you limited in how long you can work or do other activities because of your vision? — 2 | 6 |
| Q17: Are you limited in how long you can work or do other activities because of your vision? — 3 | 16 |
| Q17: Are you limited in how long you can work or do other activities because of your vision? — 4 | 17 |
| Q17: Are you limited in how long you can work or do other activities because of your vision? — 5 | 19 |
| Q17: Are you limited in how long you can work or do other activities because of your vision? — 6 | 0 |
| Q18: I stay home most of the time because of my eyesight... — 1 | 1 |
| Q18: I stay home most of the time because of my eyesight... — 2 | 11 |
| Q18: I stay home most of the time because of my eyesight... — 3 | 8 |
| Q18: I stay home most of the time because of my eyesight... — 4 | 18 |
| Q18: I stay home most of the time because of my eyesight... — 5 | 20 |
| Q18: I stay home most of the time because of my eyesight... — 6 | 0 |
| Q19: I feel frustrated a lot of the time because of my eyesight... — 1 | 2 |
| Q19: I feel frustrated a lot of the time because of my eyesight... — 2 | 22 |
| Q19: I feel frustrated a lot of the time because of my eyesight... — 3 | 8 |
| Q19: I feel frustrated a lot of the time because of my eyesight... — 4 | 10 |
| Q19: I feel frustrated a lot of the time because of my eyesight... — 5 | 16 |
| Q19: I feel frustrated a lot of the time because of my eyesight... — 6 | 0 |
| Q20: I have much less control over what I do, because of my eyesight.... — 1 | 0 |
| Q20: I have much less control over what I do, because of my eyesight.... — 2 | 11 |
| Q20: I have much less control over what I do, because of my eyesight.... — 3 | 13 |
| Q20: I have much less control over what I do, because of my eyesight.... — 4 | 20 |
| Q20: I have much less control over what I do, because of my eyesight.... — 5 | 14 |
| Q20: I have much less control over what I do, because of my eyesight.... — 6 | 0 |
| Q21: Because of my eyesight, I have to rely too much on what other people tell me. — 1 | 0 |
| Q21: Because of my eyesight, I have to rely too much on what other people tell me. — 2 | 13 |
| Q21: Because of my eyesight, I have to rely too much on what other people tell me. — 3 | 9 |
| Q21: Because of my eyesight, I have to rely too much on what other people tell me. — 4 | 16 |
| Q21: Because of my eyesight, I have to rely too much on what other people tell me. — 5 | 20 |
| Q21: Because of my eyesight, I have to rely too much on what other people tell me. — 6 | 0 |
| Q22: I need a lot of help from others because of my eyesight.. — 1 | 2 |
| Q22: I need a lot of help from others because of my eyesight.. — 2 | 9 |
| Q22: I need a lot of help from others because of my eyesight.. — 3 | 8 |
| Q22: I need a lot of help from others because of my eyesight.. — 4 | 12 |
| Q22: I need a lot of help from others because of my eyesight.. — 5 | 27 |
| Q22: I need a lot of help from others because of my eyesight.. — 6 | 0 |
| Q23: I worry about doing things that will embarrass myself or others, because of my eyesight. — 1 | 0 |
| Q23: I worry about doing things that will embarrass myself or others, because of my eyesight. — 2 | 9 |
| Q23: I worry about doing things that will embarrass myself or others, because of my eyesight. — 3 | 8 |
| Q23: I worry about doing things that will embarrass myself or others, because of my eyesight. — 4 | 13 |
| Q23: I worry about doing things that will embarrass myself or others, because of my eyesight. — 5 | 28 |
| Q23: I worry about doing things that will embarrass myself or others, because of my eyesight. — 6 | 0 |
Collected over Adverse events were monitored throughout the study (from time of admission to the clinic through the Follow-up visit on Day 32) until resolution.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/20 (0%) | 0/20 (0%) | 15/20 (75%) |
| Phentolamine Mesylate Ophthalmic Solution 0.5% | 0/20 (0%) | 0/20 (0%) | 16/20 (80%) |
| Phentolamine Mesylate Ophthalmic Solution 1.0% | 0/20 (0%) | 0/20 (0%) | 17/20 (85%) |
| Period 2 - 1.0% Phentolamine Mesylate Ophthalmic Solution | 0/57 (0%) | 0/57 (0%) | 13/57 (22.8%) |
| Event | Placebo | Phentolamine Mesylate Ophthalmic Solution 0.5% | Phentolamine Mesylate Ophthalmic Solution 1.0% | Period 2 - 1.0% Phentolamine Mesylate Ophthalmic Solution |
|---|---|---|---|---|
| Eye irritationEye disorders | 3/20 | 7/20 | 10/20 | 5/57 |
| Conjunctival hyperaemiaEye disorders | 0/20 | 4/20 | 8/20 | 0/57 |
| Product taste abnormalGeneral disorders | 2/20 | 2/20 | 7/20 | 2/57 |
| HeadacheNervous system disorders | 6/20 | 4/20 | 4/20 | 3/57 |
| Eye pruritusEye disorders | 3/20 | 5/20 | 2/20 | 1/57 |
| Dry eyeEye disorders | 1/20 | 4/20 | 1/20 | 0/57 |
| DysgeusiaNervous system disorders | 0/20 | 4/20 | 2/20 | 0/57 |
| PhotophobiaEye disorders | 0/20 | 0/20 | 3/20 | 1/57 |
| Abnormal sensation in eyeEye disorders | 1/20 | 2/20 | 1/20 | 0/57 |
| AsthenopiaEye disorders | 2/20 | 1/20 | 1/20 | 0/57 |
| Age, Continuous(Years) | Placebo | Phentolamine Mesylate Ophthalmic Solution 0.5% | Phentolamine Mesylate Ophthalmic Solution 1.0% | Total |
|---|---|---|---|---|
| Mean | 34.5 ± 8.01 | 32.3 ± 7.29 | 35.1 ± 6.60 | 34.0 ± 7.30 |
| Sex: Female, Male(Participants) | Placebo | Phentolamine Mesylate Ophthalmic Solution 0.5% | Phentolamine Mesylate Ophthalmic Solution 1.0% | Total |
|---|---|---|---|---|
| Female | 12 | 10 | 13 | 35 |
| Male | 8 | 10 | 7 | 25 |
| Race (NIH/OMB)(Participants) | Placebo | Phentolamine Mesylate Ophthalmic Solution 0.5% | Phentolamine Mesylate Ophthalmic Solution 1.0% | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 3 | 3 | 9 |
| White | 15 | 16 | 17 | 48 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 0 | 2 |
| Central Corneal Thickness (Right Eye)(um) | Placebo | Phentolamine Mesylate Ophthalmic Solution 0.5% | Phentolamine Mesylate Ophthalmic Solution 1.0% | Total |
|---|---|---|---|---|
| Mean | 550.5 ± 29.60 | 556.0 ± 29.44 | 550.4 ± 35.54 | 552.3 ± 31.23 |
| Central Corneal Thickness (Left Eye)(um) | Placebo | Phentolamine Mesylate Ophthalmic Solution 0.5% | Phentolamine Mesylate Ophthalmic Solution 1.0% | Total |
|---|---|---|---|---|
| Mean | 552.0 ± 25.51 | 554.5 ± 26.84 | 551.3 ± 34.64 | 552.6 ± 28.81 |
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2011 to primary completion in Apr 2012, 7 months.
Results were first posted in Oct 2026, 14 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Phentolamine
Opus Genetics, Inc